AI
The partnership will use Ada Health's AI-based platform to speed up the diagnosis of rare conditions.
The partnership will work on a drug discovery programme for the genetic muscle wasting disorder.
The company states that the study was designed to minimise bias in assessing the solution’s impact on diagnostic accuracy.
According to the Hong Kong-based startup, the SenseCare-Chest DR Pro can quickly identify normal and abnormal scans from chest x-ray screenings.
System which identifies patients at risk of fatal heart attack obtains CE mark.
Companies will shed light on immunotherapy, an emerging therapeutic approach that helps the immune system fight cancer, in a brand-new study on one of the most impacting cancers worldwide.
The system uses heatmaps to make AI decisions transparent to clinicians.
Also: PainChek's app picks up European and Australian regulatory clearances; Digital health access as a social determinant of health.
This Series C comes less than a year after the startup closed its $200 million Series B in 2020.
The company's technology looks to reduce the burden on pathologists reviewing digital slides, while also serving as a safety net to reduce errors.